Aligos Therapeutics, a prominent clinical-stage biopharmaceutical company focused on developing novel therapeutics for liver diseases, has announced a significant exclusive...
Obesity biotech Kailera Therapeutics has successfully entered the US public market with an upsized $625 million Initial Public Offering (IPO),...
Merck & Co. (known as MSD outside North America) has achieved a significant regulatory milestone with the European Commission (EC)...
The advent of cell and gene therapies (CGTs) marks a paradigm shift in medicine, offering transformative, potentially curative treatments for...
The pharmaceutical contract development and manufacturing organization (CDMO) sector, a critical backbone of the global drug supply chain, is increasingly...
UCB, a global biopharmaceutical company renowned for its advancements in neurology and immunology, has formally announced a definitive agreement to...
The April 2026 issue of Pharma Technology Focus delves into the critical technological and strategic shifts redefining the global pharmaceutical...
US President Donald Trump has signed a significant executive order aimed at accelerating the regulatory review and market entry of...
The global landscape for obesity pharmacotherapy is undergoing a profound transformation, with an emerging class of non-glucagon-like peptide-1 receptor (non-GLP-1R)...
Boehringer Ingelheim, a leading research-driven pharmaceutical company, has officially inaugurated a significant new artificial intelligence (AI) and machine learning (ML)...